16 related articles for article (PubMed ID: 38677937)
1. IMM-H004 protects against oxygen-glucose deprivation/reperfusion injury to BV2 microglia partly by modulating CKLF1 involved in microglia polarization.
Chen C; Ai Q; Chu S; Zhang Z; Zhou X; Luo P; Liu Y; Chen N
Int Immunopharmacol; 2019 May; 70():69-79. PubMed ID: 30785093
[TBL] [Abstract][Full Text] [Related]
2. IMM-H004 Protects against Cerebral Ischemia Injury and Cardiopulmonary Complications via CKLF1 Mediated Inflammation Pathway in Adult and Aged Rats.
Ai Q; Chen C; Chu S; Luo Y; Zhang Z; Zhang S; Yang P; Gao Y; Zhang X; Chen N
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987181
[TBL] [Abstract][Full Text] [Related]
3. IMM-H004, a novel coumarin derivative compound, attenuates the production of inflammatory mediatory mediators in lipopolysaccharide-activated BV2 microglia.
Song XY; Hu JF; Sun MN; Li ZP; Zhu ZX; Song LK; Yuan YH; Liu G; Chen NH
Brain Res Bull; 2014 Jul; 106():30-8. PubMed ID: 24878446
[TBL] [Abstract][Full Text] [Related]
4. IMM-H004 therapy for permanent focal ischemic cerebral injury via CKLF1/CCR4-mediated NLRP3 inflammasome activation.
Ai QD; Chen C; Chu S; Zhang Z; Luo Y; Guan F; Lin M; Liu D; Wang S; Chen N
Transl Res; 2019 Oct; 212():36-53. PubMed ID: 31176667
[TBL] [Abstract][Full Text] [Related]
5. IMM-H004, a novel courmarin derivative, protects against oxygen-and glucose-deprivation/restoration-induced apoptosis in PC12 cells.
Ji HJ; Wang DM; Hu JF; Sun MN; Li G; Li ZP; Wu DH; Liu G; Chen NH
Eur J Pharmacol; 2014 Jan; 723():259-66. PubMed ID: 24291097
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum to "IMM-H004 protects against oxygen-glucose deprivation/reperfusion injury to BV2 microglia partly by modulating CKLF1 involved in microglia polarization" [Int. Immunopharmacol. 70 (2019) 69-79].
Chen C; Ai QD; Chu SF; Zhang Z; Zhou X; Luo P; Liu YJ; Chen NH
Int Immunopharmacol; 2024 May; 133():112154. PubMed ID: 38677937
[No Abstract] [Full Text] [Related]
7. Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6 / NF-kappaB signaling pathway.
Li R; Jia H; Si M; Li X; Ma Z; Zhu Y; Sun W; Zhu F; Luo S
Eur J Pharmacol; 2023 Aug; 953():175860. PubMed ID: 37331681
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
